CTMX Q2 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M-1.9% YoY

Gross Profit

$16M100.0% margin

Operating Income

-$19M-117.9% margin

Net Income

-$19M-118.1% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$402M

Total Liabilities

$271M

Stockholders' Equity

$131M

Cash & Equivalents

$256M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$17M	-1.9%
Gross Profit	$16M	$17M	-1.9%
Operating Income	-$19M	-$16M	-19.0%
Net Income	-$19M	-$16M	-22.7%